A Phase 1 bioequivalence study between the current commercial formulation and the proposed soft gel capsule formulation of talazoparib, and food effect study for the proposed talazoparib soft gel capsule formulation in participants with advanced solid tumor

Project: Research

Project Details

Project Description

NMA HREC Reference Number: 70013
NMA SSA Reference Number: SSA/70013/MonH-2021-251949(v1)
Monash Health Reference: RES-20-0000-857A
Effective start/end date13/01/2112/01/26


  • phase 1 study
  • treatment efficacy
  • treatment safety
  • solid tumour